Biodexa Pharmaceuticals Files 6-K Report

Ticker: BDRX · Form: 6-K · Filed: Sep 19, 2024 · CIK: 1643918

Biodexa Pharmaceuticals PLC 6-K Filing Summary
FieldDetail
CompanyBiodexa Pharmaceuticals PLC (BDRX)
Form Type6-K
Filed DateSep 19, 2024
Risk Levellow
Pages1
Reading Time1 min
Sentimentneutral

Sentiment: neutral

Topics: disclosure, foreign-private-issuer, regulatory-filing

Related Tickers: BDRX

TL;DR

Biodexa Pharma (BDRX) filed a 6-K, standard disclosure for foreign issuers.

AI Summary

Biodexa Pharmaceuticals PLC, formerly Midatech Pharma Plc, filed a Form 6-K on September 19, 2024. The company, located at 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom, is a foreign private issuer. This filing is for the month of September 2024 and indicates the company files annual reports under Form 20-F.

Why It Matters

This filing provides an update on Biodexa Pharmaceuticals' regulatory status and reporting, which is important for investors tracking the company's compliance and disclosures.

Risk Assessment

Risk Level: low — This filing is a routine disclosure for a foreign private issuer and does not contain significant new financial or operational information.

Key Numbers

Key Players & Entities

FAQ

What is the purpose of a Form 6-K filing?

A Form 6-K is a report of foreign private issuers pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to furnish information which the issuer makes or is required to make public in its home country.

What is the former name of Biodexa Pharmaceuticals PLC?

The former name of Biodexa Pharmaceuticals PLC was Midatech Pharma Plc, with a date of name change on June 2, 2015.

Where is Biodexa Pharmaceuticals PLC located?

Biodexa Pharmaceuticals PLC is located at 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom.

What is the SEC file number for Biodexa Pharmaceuticals PLC?

The SEC file number for Biodexa Pharmaceuticals PLC is 001-37652.

Does Biodexa Pharmaceuticals PLC file annual reports under Form 20-F?

Yes, the filing indicates by check mark that the registrant files annual reports under cover of Form 20-F.

Filing Stats: 248 words · 1 min read · ~1 pages · Grade level 16.4 · Accepted 2024-09-19 16:30:18

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Biodexa Pharmaceuticals PLC (Registrant) Date: September 19, 2024 /s/ Stephen Stamp Stephen Stamp Chief Executive Officer, Chief Financial Officer

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing